Production of human CAR-NK cells with lentiviral vectors and functional assessment in vitro

Portillo, Ana L.; Hogg, Richard T.; Ashkar, Ali A.

doi:10.1016/j.xpro.2021.100956

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A final risk worth noting is the application of retroviruses. CAR-T/NK therapies typically use lentiviruses to introduce CAR genes into cells [ 141 ], and the use of such systems relies on well-defined viral packaging methods. To date, there has been no mention of how this randomized integration affects clinical outcomes for patients.…”

Section: Current Clinical Trials Of Car-nkmentioning

confidence: 99%

Current Progress of CAR-NK Therapy in Cancer Treatment

Pang

Wang

et al. 2022

Cancers

View full text Add to dashboard Cite

CD8+ T cells and natural killer (NK) cells eliminate target cells through the release of lytic granules and Fas ligand (FasL)-induced target cell apoptosis. The introduction of chimeric antigen receptor (CAR) makes these two types of cells selective and effective in killing cancer cells. The success of CAR-T therapy in the treatment of acute lymphoblastic leukemia (ALL) and other types of blood cancers proved that the immunotherapy is an effective approach in fighting against cancers, yet adverse effects, such as graft versus host disease (GvHD) and cytokine release syndrome (CRS), cannot be ignored for the CAR-T therapy. CAR-NK therapy, then, has its advantage in lacking these adverse effects and works as effective as CAR-T in terms of killing. Despite these, NK cells are known to be hard to transduce, expand in vitro, and sustain shorter in vivo comparing to infiltrated T cells. Moreover, CAR-NK therapy faces challenges as CAR-T therapy does, e.g., the time, the cost, and the potential biohazard due to the use of animal-derived products. Thus, enormous efforts are needed to develop safe, effective, and large-scalable protocols for obtaining CAR-NK cells. Here, we reviewed current progress of CAR-NK therapy, including its biological properties, CAR compositions, preparation of CAR-NK cells, and clinical progresses. We also discussed safety issues raised from genetic engineering. We hope this review is instructive to the research community and a broad range of readers.

show abstract

Section: Current Clinical Trials Of Car-nkmentioning

confidence: 99%

Current Progress of CAR-NK Therapy in Cancer Treatment

Pang

Wang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…They have, however, also been marred by potential risks of toxicity and inflammation because of the nature of the vector. Lentiviral and non-lentivirus retroviral vectors have been successful in transducing NK cells, 48 , 49 , 50 but no universally accepted protocol currently exists. Different labs have found success with different vectors, although some have been more common than others.…”

Section: Introductionmentioning

confidence: 99%